Bayer(BAYRY)

Search documents
Bayer (BAYRY) Intends to Slash Dividends Amid Challenges
Zacks Investment Research· 2024-02-20 14:50
Bayer AG (BAYRY) announced plans to cut its dividend rate for 2023.Following a review of the company’s capital allocation priorities to reduce debt, BAYRY plans to amend its dividend policy to pay out only the legally required minimum for three years.Consequently, the decision will reduce the dividend to €0.11 per share for 2023 compared with €2.40 in 2022.This proposal comes as the company faces a high level of debt, coupled with high-interest rates and a challenging free cash flow situation.The ongoing gl ...
Bayer to pay $2.25B after jury says Roundup weed killer gave man cancer
New York Post· 2024-01-30 15:54
Bayer was ordered to pay $2.25 billion after a Pennsylvania jury unanimously ruled that its Roundup weed killer gave a man cancer.John McKivinson, 49, who was diagnosed with non-Hodgkin’s lymphoma, sued Roundup maker Monsanto and its corporate parent, Bayer, saying he developed the cancer after using the herbicide on his property for two decades.The massive payout includes $2 billion in punitive damages, McKivinson’s attorneys at Kline & Specter told The Post on Tuesday.Jury members also found that Monsant ...
Bayer downgraded over 'multiple adverse factors' faced in 2024
Proactive Investors· 2024-01-10 13:55
Bayer AG (ETR:BAYN, OTC:BAYZF) will find it tough to hit last year's targets and faces multiple adverse factors in 2024, said Stifel as it downgraded the German pharma giant and cut its share price target. The US bank removed its 'buy' rating with a switch to a 'hold' stance with a reduced price target of €42 from €68. Analysts think Bayer "will find it tough" to reach the lower end of the 2023 earnings guidance of €11.3 billion excluding current effects. According to new Bayer chief executive Bill Anders ...
Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies
Zacks Investment Research· 2024-01-08 17:47
Bayer AG (BAYRY) announced that the late-stage studies on the investigational compound elinzanetant were successful.Elinzanetant is the first dual neurokinin-1,3 receptor antagonist in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (“VMS”), also known as hot flashes associated with menopause, administered orally once daily.The phase III studies, OASIS 1 and 2 are double-blind, randomized, placebo-controlled multicenter studies investigating the effica ...
Moderna, Bayer-backed genetic therapies company files for IPO
Proactive Investors· 2024-01-08 17:04
About this content About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine. Read more About the publisher Pr ...
Bayer(BAYRY) - 2023 Q3 - Earnings Call Presentation
2023-11-08 15:25
| --- | --- | --- | --- | |-----------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Q3 2023 | | | | | Investor Webinar //////////////// | | | | | November 8th, 2023 | | | | Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between ...
Bayer(BAYRY) - 2023 Q3 - Earnings Call Transcript
2023-11-08 15:19
Bayer Aktiengesellschaft (OTCPK:BAYZF) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Jost Reinhard - Senior Vice President & Head-Investor Relations Bill Anderson - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Heiko Schipper - President, Consumer Health Division Conference Call Participants Peter Verdult - Citi Sachin Jain - Bank of America Vincent An ...
Bayer(BAYRY) - 2023 Q2 - Earnings Call Transcript
2023-08-08 17:23
Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill Anderson - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Heiko Schipper - President, Consumer Health Division Conference Call Participants Michael Leuchten - UBS Richard Vosser - JPMorgan James Quigley - Morgan Stanley Peter Verdult - Citigroup Sachin Jain - Bank of America Vince ...
Bayer(BAYRY) - 2023 Q2 - Earnings Call Presentation
2023-08-08 12:11
| --- | --- | --- | --- | |--------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Q2 2023 | | | | | Investor Call //////////////// | | | | | August 8th, 2023 | | | | Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the act ...
Bayer(BAYRY) - 2023 Q1 - Earnings Call Presentation
2023-05-17 16:49
| --- | --- | --- | --- | |----------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Investor Conference Call Q1 2023 //////////////// | | | | | May 11th, 2023 | | | | Cautionary Statements Regarding Forward-Looking Information | --- | --- | --- | |-------|--------------------------------|-------| | | | | | | | | | | | | | | | | | | The company assumes no | | | | | | | | | | | | liability whatsoever to update | | | | | | | | | | | | these forward-looking | ...